SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as community members discuss its recent listing and availability on Phantom Wallet. The Solana-based token is being touted for its potential gains, with many highlighting its strong momentum and comparing it to other meme coins. Some users note its relative stability amidst broader market volatility.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as investors react to President Trump's comments on trade relations with China, which have injected volatility into the market. Community members are actively discussing potential market impacts and the effectiveness of tariff strategies. The ETF is caught in broader market uncertainty amidst concerns about global economic tensions.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

VTI is trending amid discussions about market conditions and potential corrections, influenced by factors like tariff impacts, government shutdowns, and AI developments. Community members are actively debating the ETF's performance relative to other investment options and reacting to news impacting its diverse holdings, such as political events and economic data. Conversations also include discussions around diversification, portfolio strategy, and individual stock picks versus broader market ETFs.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors assess the impact of a recent FDA safety notice regarding hypersensitivity reactions to specific lots of intravenous immune globulin, including some ADMA products; the community is weighing the potential financial impact of voluntary withdrawals and discussing whether a recent stock sale by the CEO is related to the news. Some see the dip as a buying opportunity given the company's growth and buyback program, while others express concern about potential revenue impacts and are awaiting further updates from management.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the community rallies behind it as the top memecoin on Bitcoin, emphasizing its fair launch and strong community-driven nature. Discussions highlight its potential to outperform other memecoins and its unique position within the Bitcoin ecosystem. Community members are actively promoting its listing on major exchanges and emphasizing its potential for significant growth.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF (BTC) is trending amid broader cryptocurrency market discussions, particularly around Solana-based tokens. Community chatter highlights enthusiasm for Solana projects, with the stock also influenced by Bitcoin's overall market movements and potential integration with AI technologies.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst discussions on tariffs, CPI, and their potential impact, with community members debating whether previous losses have been recovered adequately. Chatter includes short interest, potential revenue beats, and forward-looking market valuation. The stock is also reacting to broader market forces like gold price fluctuations and sector-specific news from competitors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid anticipation for its Super App release and upcoming listings on major exchanges like Coinbase and Binance. The community is bullish, drawing comparisons to XRP and highlighting potential NBA and NHL sponsorships. Discussions also involve the project's utility in payroll and staking rewards through Uphold.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around a potential options play and broader market reactions to political news. Community members are expressing varied opinions on the stock, with some focusing on the company's fundamentals, while others discuss its relationship to political events and figures. The stock's movements are being closely watched within the context of ongoing political and economic developments.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

TRON is trending as the community discusses its strong ties to Rumble and Tether, including a potential Rumble wallet for content creators and cloud deals. The crypto's resilience amid market volatility is also noted, with some anticipating further upside and a potential Coinbase listing. Overall, the conversation revolves around Tron's growing adoption and integrations within the crypto space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate was 27% in patients with a median follow-up of 9.4 months.&nbsp;</li><li>The company also announced the pricing of an underwritten offering of 21 million shares of its common stock and pre-funded warrants to purchase up to 3.2 million shares of its common stock. &nbsp;</li></ul>Tango Therapeutics, Inc. (TNGX) on Thursday announced $225 million in financing on the heels of positive data from its ongoing study of Vopimetostat in patients with MTAP-deleted cancers.CEO Barbara Weber <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/23/3171895/0/en/Tango-Therapeutics-Reports-Positive-Data-from-Ongoing-Phase-1-2-Study-with-Vopimetostat-TNG462-in-Patients-with-MTAP-deleted-Cancers.html">said</a> that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median progression-free survival of 6.4 months.In 2L MTAP-deleted pancreatic cancer, the median progression-free survival (PFS) was 7.2 months, and the ORR was 25% in the study. The company now expects to initiate a pivotal trial in MTAP-deleted pancreatic cancer patients who have received one prior line of therapy in 2026, with about 300 patients. The company is slated to consult with the U.S. Food and Drug Administration on trial design later this quarter.Vopimetostat is being evaluated as a monotherapy and in combination clinical studies. According to Tango, methylthioadenosine phosphorylase (MTAP) deletions occur in 10-15% of all human cancers, including approximately 35% of pancreatic cancers and 15% of lung cancers. This loss creates a metabolic vulnerability because the MTAP enzyme normally breaks down methylthioadenosine (MTA), which is toxic when it builds up.<h2 class="st-heading-2">Financing Details</h2>The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/23/3171915/0/en/Tango-Therapeutics-Announces-225-Million-Financing.html">announced</a> the pricing of an underwritten offering of 21 million shares of its common stock and pre-funded warrants to purchase up to 3.2 million shares of its common stock. The offering price of each share of common stock is $8.66, it stated. The gross proceeds from the offering is expected to be about $210 million, it added.The offering is expected to close on or about October 24, subject to customary conditions. Participants in the offering include a large, unnamed institutional investor, in addition to Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, and others, the company said.Tango added that it has also entered into a securities purchase agreement for a private investment in public equity and is selling about 1.7 million shares of its common stock for $8.66 per share to raise gross proceeds of about $15 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TNGX">TNGX shares</a> traded 8% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around TNGX jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.TNGX stock is up by 180% this year and by about 38% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tango Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy

CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months. 

Equity

Tango Therapeutics (TNGX) Soars 7.8%: Is Further Upside Left in the Stock?

Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates

Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?

The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

5 Biotech Stocks with Highly Anticipated Pending Results

Others

Biotech M&A is heating up, making small-cap firms with breakthrough assets top acquisition targets and potential big winners for investors.

Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$7.51
Beta	1.20
Avg. Volume	2.59M
PE Ratio	-5.64

52-Week High	$9.70
52-Week Low	$1.03
Market Capitalization	$833.89M
EPS (Annual)	-$1.19
Price to Book	6.16
Revenue Per Employee	$271,412.90
Enterprise Value/EBITDA	N/A

TNGX
Tango Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNGX News

TNGXTango Therapeutics Inc